logo
#

Latest news with #FatimaAlKaabi

UAE first to approve oral therapy for rare autoimmune disorder
UAE first to approve oral therapy for rare autoimmune disorder

Dubai Eye

time08-07-2025

  • Health
  • Dubai Eye

UAE first to approve oral therapy for rare autoimmune disorder

The UAE has become the first country in the world to approve an oral therapy for a rare autoimmune disorder. The newly authorised drug, Rilzabrutinib, targets Immune Thrombocytopenia - a condition that affects just a few individuals per 100,000 worldwide. Developed by global pharmaceutical company Sanofi, Rilzabrutinib is the first oral Bruton's tyrosine kinase inhibitor to be approved for this condition. The treatment works by restoring immune system balance and increasing platelet counts, offering patients faster relief and improved quality of life. Clinical studies have demonstrated promising outcomes, with patients reporting substantial improvement in health indicators. Dr. Fatima Al Kaabi, Director-General of the Emirates Drug Establishment, says the approval reflects the UAE's commitment to pioneering advanced therapies and strengthening its role as a regional leader in pharmaceutical innovation. #WamNews — WAM English (@WAMNEWS_ENG) July 8, 2025

UAE first to approve oral therapy for rare autoimmune disorder
UAE first to approve oral therapy for rare autoimmune disorder

TAG 91.1

time08-07-2025

  • Health
  • TAG 91.1

UAE first to approve oral therapy for rare autoimmune disorder

The UAE has become the first country in the world to approve an oral therapy for a rare autoimmune disorder. The newly authorised drug, Rilzabrutinib, targets Immune Thrombocytopenia - a condition that affects just a few individuals per 100,000 worldwide. Developed by global pharmaceutical company Sanofi, Rilzabrutinib is the first oral Bruton's tyrosine kinase inhibitor to be approved for this condition. The treatment works by restoring immune system balance and increasing platelet counts, offering patients faster relief and improved quality of life. Clinical studies have demonstrated promising outcomes, with patients reporting substantial improvement in health indicators. Dr. Fatima Al Kaabi, Director-General of the Emirates Drug Establishment, says the approval reflects the UAE's commitment to pioneering advanced therapies and strengthening its role as a regional leader in pharmaceutical innovation. Emirates Drug Establishment approves world's first oral therapy for immune thrombocytopenia #WamNews — WAM English (@WAMNEWS_ENG) July 8, 2025

Emirates Drug Establishment approves world's first oral therapy for immune thrombocytopenia
Emirates Drug Establishment approves world's first oral therapy for immune thrombocytopenia

Al Etihad

time08-07-2025

  • Business
  • Al Etihad

Emirates Drug Establishment approves world's first oral therapy for immune thrombocytopenia

8 July 2025 14:37 ABU DHABI (WAM) The Emirates Drug Establishment (EDE) has granted official approval for Rilzabrutinib, the first oral Bruton's tyrosine kinase (BTK) inhibitor to be authorised in the country for the treatment of Immune Thrombocytopenia (ITP), a rare autoimmune disorder that affects approximately 2 to 5 individuals per 100,000 people this landmark approval, the UAE becomes the first country in the world to authorise this innovative medication, reflecting the nation's global leadership in accelerating access to advanced treatments and addressing critical medical approval of Rilzabrutinib in the UAE represents a major step forward, offering patients with ITP early access to a pioneering therapeutic solution that contributes to a faster treatment journey and a tangible improvement in quality of decision aligns with the UAE's strategic commitment to ensuring the availability of high-efficacy, globally benchmarked treatments in line with the highest international standards and by global pharmaceutical and healthcare company Sanofi, Rilzabrutinib represents a breakthrough in restoring immune system balance by targeting the underlying cause of increasing platelet counts, the treatment addresses both the symptoms and root causes of the condition. Clinical studies have demonstrated promising outcomes, with patients reporting substantial improvement in health Fatima Al Kaabi, Director-General of the Emirates Drug Establishment, stated, 'The UAE is committed to providing access to the world's latest therapeutic innovations and further promoting its position as a regional hub for pharmaceutical excellence. With Rilzabrutinib getting approved, we take another step further in achieving our strategy aimed at enhancing national pharmaceutical security, implementing advanced treatment protocols, and streamlining regulatory frameworks in collaboration with international partners.'Dr. Al Kaabi emphasised that the milestone demonstrates the effectiveness of the UAE's proactive healthcare policies and flexible regulatory systems in fostering innovation and facilitating patient access to advanced medications.'The Emirates Drug Establishment will spare no effort to accelerate regulatory procedures, and strengthen global partnerships,' she said. 'This further solidifies the UAE's role as a regional centre for pharmaceutical innovation.'She added, 'Granting approval for Rilzabrutinib reaffirms the Establishment's commitment to fast-tracking access to transformative therapies that create significant impact, particularly in the treatment of rare and chronic diseases. EDE will continue to adopt a proactive, innovation-driven approach, fuelled by international collaboration, to ensure that safe, effective therapeutic options are available across the country in accordance with the highest global standards. Our goal is to enhance the UAE's health system preparedness in an era of rapid scientific progress.' For her part, Preeti Futnani, MCO Lead and General Manager, Specialty Care for KSA & Gulf Countries at Sanofi, said, 'We are honoured to collaborate with the Emirates Drug Establishment to bring this groundbreaking treatment to patients in the UAE living with Immune Thrombocytopenia. The approval of Rilzabrutinib demonstrates our shared commitment to placing patients at the centre of our mission and delivering cutting-edge solutions that address some of the most pressing unmet medical needs.'

Erth Zayed Philanthropies donates Dhs25m to NMSS
Erth Zayed Philanthropies donates Dhs25m to NMSS

Gulf Today

time01-06-2025

  • Health
  • Gulf Today

Erth Zayed Philanthropies donates Dhs25m to NMSS

The National Multiple Sclerosis Society (NMSS) has signed a strategic agreement with Erth Zayed Philanthropies to advance its national multiple sclerosis (MS) agenda. As part of this agreement, Erth Zayed Philanthropies will contribute Dhs25 million to support NMSS in delivering its core priorities, including advancing UAE's first National Coalition for MS, a multi-sector platform to improve care, research, and inclusion across the country. The agreement was signed by Dr. Fatima Al Kaabi, Vice Chair of the National Multiple Sclerosis Society, and a representative from Erth Zayed Philanthropies during a formal ceremony in Abu Dhabi. The announcement of this strategic agreement coincides with World MS Day, marked this year under the global theme 'My MS Diagnosis: Navigating MS Together,' which highlights the importance of early detection and community support. This year, Erth Zayed Philanthropies joins the National Coalition for MS as a founding partner, marking a pivotal step in the UAE's efforts to advance equitable MS care and inclusion. This strategic partnership reinforces the UAE's commitment to enhancing MS care, accelerating research, and advancing equity, catalysing broader multi-sector engagement to shape a more inclusive and transformative national response. Coalition members include Sanofi, Axios International, PureHealth and Manzil Healthcare Services, each playing a vital role in advancing care, awareness, and system-wide impact. Dr. Fatima Al Kaabi said, 'The establishment of the National Coalition for MS is a defining step in our mission to drive equitable access to MS care. This work is inspired by the legacy of our Founding Father, the late Sheikh Zayed bin Sultan Al Nahyan, whose vision was rooted in dignity, inclusion, and access to quality care for all. It is sustained by the leadership of President His Highness Sheikh Mohamed Bin Zayed Al Nahyan, whose commitment continues to shape the future of health and reinforce the UAE's position as a global leader in innovative, people-centered healthcare.' 'On World MS Day, we are proud to join the international community, not only in raising awareness, but in taking meaningful, coordinated action that has the potential to transform outcomes for people living with MS. Today, we are laying the foundations for long-term impact rooted in compassion, powered by collaboration, and guided by a shared responsibility to ensure that every member of our community has the opportunity to live a full and dignified life.' WAM

NMSS, Erth Zayed Philanthropies sign Dh25 million grant agreement to mark "World MS Day"
NMSS, Erth Zayed Philanthropies sign Dh25 million grant agreement to mark "World MS Day"

Al Etihad

time30-05-2025

  • Health
  • Al Etihad

NMSS, Erth Zayed Philanthropies sign Dh25 million grant agreement to mark "World MS Day"

30 May 2025 18:10 ABU DHABI (ALETIHAD)The National Multiple Sclerosis Society (NMSS) has signed a strategic agreement with Erth Zayed Philanthropies to advance its national multiple sclerosis (MS) agenda. As part of this agreement, Erth Zayed Philanthropies will contribute Dh 25 million to support NMSS in delivering its core priorities, including advancing UAE's first National Coalition for MS, a multi-sector platform to improve care, research, and inclusion across the agreement was signed by Dr. Fatima Al Kaabi, Vice Chair of the National Multiple Sclerosis Society, and a representative from Erth Zayed Philanthropies during a formal ceremony in Abu announcement of this strategic agreement coincides with World MS Day, marked this year under the global theme 'My MS Diagnosis: Navigating MS Together,' which highlights the importance of early detection and community year, Erth Zayed Philanthropies joins the National Coalition for MS as a founding partner, marking a pivotal step in the UAE's efforts to advance equitable MS care and inclusion. This strategic partnership reinforces the UAE's commitment to enhancing MS care, accelerating research, and advancing equity, catalyzing broader multi-sector engagement to shape a more inclusive and transformative national response. Coalition members include Sanofi, Axios International, PureHealth and Manzil Healthcare Services, each playing a vital role in advancing care, awareness, and system-wide Fatima Al Kaabi, Vice Chair of NMSS, said: 'The establishment of the National Coalition for MS is a defining step in our mission to drive equitable access to MS care." She added, "This work is inspired by the legacy of our late Founding Father, Sheikh Zayed bin Sultan Al Nahyan, whose vision was rooted in dignity, inclusion, and access to quality care for all. It is sustained by the leadership of President His Highness Sheikh Mohamed bin Zayed Al Nahyan, whose commitment continues to shape the future of health and reinforce the UAE's position as a global leader in innovative, people-centred healthcare."She stated: 'On World MS Day, we are proud to join the international community, not only in raising awareness, but in taking meaningful, coordinated action that has the potential to transform outcomes for people living with MS. Today, we are laying the foundations for long-term impact rooted in compassion, powered by collaboration, and guided by a shared responsibility to ensure that every member of our community has the opportunity to live a full and dignified life.'The grant from Erth Zayed Philanthropies aims to directly support NMSS in delivering on its key priorities and enabling the National Coalition for MS to address the most pressing challenges faced by people living with MS in the the National Coalition for MS was convened by NMSS to bring together government entities, healthcare providers, insurance and pharmaceutical companies, and educational institutions under a unified national agenda for MS. The Coalition's priorities for 2025-2026 are focused on improving access to patient support resources, promoting inclusive workplace policies, strengthening the skills of healthcare professionals through specialised training, increasing public understanding of MS to enable earlier diagnosis, and ensuring long-term sustainability through coordinated fundraising and investment in priorities form an action-oriented framework designed to mobilise resources, strengthen inclusion across sectors, and ensure that the UAE is a world leader in MS care. As the Coalition moves into its implementation phase, its priorities will continue to be shaped by the voices and experiences of the MS community, ensuring that their needs, priorities, and aspirations drive every step of the in shared responsibility and measurable impact, the Coalition's members are onboarded to lead or contribute to key initiatives, with defined commitments that span one to two years depending on the scope of Coalition's priorities reflect a commitment to evidence-based solutions. Since its establishment, NMSS has invested Dh 6.5 million in MS research, with the next NMSS research grant cycle set to launch on June 23, 2025. As the Coalition transitions into its implementation phase, NMSS continues to call on stakeholders across sectors, from policymakers and healthcare institutions to academic bodies and donors, to join this pivotal movement. Source: Aletihad - Abu Dhabi

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store